Master Students 2025
6 master students finish their degree in Biochemistry and Molecular Biology or Biomedicine with projects in our lab.
Ida Emilie Jørgensen - exploring the function of the RBM12 protein and mutations in RBM12 in relation to disease.
Lærke Borgen Mikkelsen - exploring SSO-based modulation of LRRK2 gene expression in Parkinson's Disease
Agnethe Rullhøj Knudsen defended her thesis Investigation Pseudoexon Activation in HTT for Therapeutic Potential
Sicha Jagd Hersdorf explored manipulation of OGA with SSOs and the complex splicing associated with it.
Gry Kirkebak investigated the manipulation LRP6 pseudoexons.
Sofie Sjølund Christensen explored how pseudoexons in 5' UTR region can affect gene expression.
Inverna Therapeutics
Inverna Therapeutics is a biotech company established in 2025 as a spin-off of the RNA Splicing and Disease research group.
Inverna Therapeutics is dedicated to developing transformative RNA therapeutics based on RNA splicing modulation.